



AdisInsight User Guide

July 2015


Table of Contents

- [Registering an account on AdisInsight](#)
- [Log In](#)
- [AdisInsight Subscription Access](#)
- [Basic Search](#)
- [Advanced Search](#)
- [Refine Your Search](#)
- [Viewing a DRUG Profile Record](#)
- [Viewing a TRIAL Profile Record](#)
- [Viewing a SAFETY Profile Record](#)
- [Viewing a DEAL Profile Record](#)
- [Chemical Structure Search](#)
- [Exporting Data](#)
- [Exporting Results \(CSV\)](#)
- [Exporting Data Table](#)
- [Export BizInt](#)
- [How to use BizInt Charting Tool](#)
- [Saving Searches](#)
- [Setting up Email Alerts](#)
- [How to provide Feedback](#)
- [Who to contact](#)


Registering an account on AdisInsight

Creating an account with a username and password allows you to personalize your experience, including setting up **saved searches** and **up email alerts**. To register:

- Visit <http://AdisInsight.Springer.com>
- Click the “Sign up/Log in” link in the upper right hand corner



Registering an account on AdisInsight



Don't have an account?

Creating an account is easy, and helps us give you a more personalised experience.

Your Springer account is shared across many Springer sites including SpringerLink, Springer Materials, Adis Insight, and Springer.com.

First Name

Last Name

Email Address

Your email address will be kept private

Password


Password Confirmation

Minimum 6 characters including at least 1 letter and 1 number

By creating an account you agree to accept our [terms of use](#)

- Complete the form under the heading “Don’t have an account?”
- If your institution has IP authenticated access you will be able to access the content straight away.
- If you’re not accessing from a registered IP range, your institution’s Administrator will need to associate your account to enable access

Log In




The screenshot shows the AdisInsight website interface. At the top, the AdisInsight logo is on the left, and a navigation bar on the right contains a link labeled "» Sign up / Log in" which is highlighted with an orange box. Below the logo is a search bar with the text "Search: by Drug Name" and a magnifying glass icon. A "Query Builder" link is also present. On the left side, there is a "Feedback" button. The main content area features a "Welcome back. Please log in." message. Below this is a login form with two input fields: "Email" and "Password", both highlighted in yellow. A "Log in" button is positioned below the email field. To the right of the password field is a link labeled "Forgotten password?" which is also highlighted with an orange box. Below the login form are two additional links: "» Log in via Shibboleth or Athens" and "» Problems logging in?".

- Once you have registered for an account, you can then access the log in screen by clicking on the “Sign up/Log in” link in the upper right hand corner and entering your email address and password
- Click the “Forgotten password?” link if you need help

AdisInsight Subscription Access

- AdisInsight allows you access to all the content sets to which you subscribe. If you subscribe to all content: DRUGS, TRIALS, SAFETY, DEALS you will be able to seamlessly move from tab to tab
- If you only subscribe to one content set (e.g. DRUGS) you will have access to all content for the DRUGS tab, but only a restricted view for the other content sets.




The screenshot displays the AdisInsight web application interface. On the left, there is a sidebar with a 'Feedback' button and a list of categories including 'Drug Name', 'Mechanism Of Action', and 'Drug Class'. The main content area shows a table of 'Safety Reports' with columns for 'Drug Name' and 'Count'. The table lists drugs like Atorvastatin, Simvastatin, Pravastatin, Fluvastatin, and Rosuvastatin. A 'Showing 3 of 305 safety reports' message is visible. A large yellow warning box is overlaid on the right side of the screen, containing the text: 'Restricted Access. Please login to view all content and gain access to the full functionality of the AdisInsight database.' Below this, a link 'click here' is provided. A smaller version of the same warning box is also visible at the bottom of the screen.

Restricted Access
Please [login](#) to view all content and gain access to the full functionality of the AdisInsight database.

Interested in a subscription?
To learn more about AdisInsight or to find out how to get access, please [click here](#)

Restricted Access
Please [login](#) to view all content and gain access to the full functionality of the AdisInsight database.


Getting Started: Using 'Search' or 'Advanced Search'



- From the home page, begin your quick search by selecting Drug Name, Indication, Mechanism of Action, Drug Class, Adverse Event, OR Full text from the drop down menu and ENTER your SEARCH TERM
- OR, to create an advanced query, click the ADVANCED SEARCH link

Basic Search


- From the home page, you can immediately begin searching using the quick search options included in the dropdown menu:
 - Drug Name
 - Indication
 - Mechanism
 - Drug Class
 - Adverse Event
 - All Text



- Once you have made a selection, start typing your query into the search box
- The autosuggest list will offer matching search terms, select from the list or continue typing
- Click on the blue search button (magnifying glass) or hit enter to retrieve search results

Advanced Search


- To conduct an advanced search query, click on 'Advanced Search' on the home page



- This will bring you to a page allowing you to build a complex query choosing from a wide selection of parameters

Advanced Search

- The Advanced Search Query Builder allows you to create a simple or complex search query that returns the most relevant and precise results.
- To create your search, start by selecting a search term from 'Frequently Searched' or 'All Search Criteria'



The screenshot displays the 'Advanced Search' interface. On the left, a sidebar contains a list of search criteria categories. The 'All Search Criteria' option is highlighted with an orange box, and an orange arrow points from this box to a larger panel on the right. The main panel is titled 'Advanced Search' and features a 'Frequently Searched' section with links to 'Adverse Event', 'Drug Name', 'Drug Class', 'Full Text', and 'Indication'. Below this, there is a section for 'Your query where' and a 'Start Over' button. The right panel shows a grid of search criteria organized alphabetically from A to Z. The criteria listed include: Adverse Event, Highest Phase, Mechanism of Action, Drug Class, Indication, Organisation, Drug Name, Journal Name, Phase, EPhMRA code, Location, Publication Country, Full Text, and Therapeutic Area.

Advanced Search

Frequently Searched

- Adverse Event
- Drug Name
- Drug Class
- Full Text
- Indication

▶ All Search Criteria

Your query where

Start Over

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


A Adverse Event	H Highest Phase	M Mechanism of Action
D Drug Class	I Indication	O Organisation
Drug Name	J Journal Name	P Phase
E EPhMRA code	L Location	Publication Country
F Full Text		T Therapeutic Area

Advanced Search

- Once your term is selected, you can see an approximate count for the results you will receive.
- You can add as many search terms to your query as you would like clicking “Show Results”

Advanced Search

Frequently Searched [Adverse Event](#)
[Drug Name](#)
[Drug Class](#)
[Full Text](#)
[Indication](#)

Mechanism of Action
 Add
[Hierarchy View](#) 


► All Search Criteria

Your query where Mechanism of Action x Is ▼ Beta-blockers x

will result in approximately 115 Drugs, 368 Trials, 2,066 Safety Reports and 33 Deals

[Start Over](#) [Show Results](#)

Refine Your Search

- From the search results page, you can further refine your search using the filters on the left-hand menu.
- Filters on the left show you at-a-glance, the top 5 counts for each criteria are shown
- You can apply as many filters as you choose OR click the  to remove filters
- The added criteria will appear in orange for easy identification

Refine Your Search

Search results for **Mechanism of Action: "Beta-blockers"**

15 Drugs 366 Trials 2,064 Safety Reports 33 Deals

Filtered by
Indication: **Hypertension** ✕ Location: **Asia** ✕ Drug Class: **Small molecules** ✕

Reset Filters

Showing 15 of 15 drugs Sort by: Update date ▼ Export ▼

Indication [see all](#)

- ☒ **Hypertension** 15
- ☐ Cardiovascular disorders 23
- ☐ Heart failure 8
- ☐ Glaucoma 6
- ☐ Ocular hypertension 6

Phase

- ☐ Marketed 6
- ☐ Phase III 3
- ☐ Phase I 1
- ☐ No development reported 2
- ☐ Discontinued 4

Location [see all](#)

- ☒ **Asia** 15
- ☐ Europe 9
- ☐ Japan 6
- ☐ USA 6

Amlodipine/bisoprolol 08 Jul 2015
Beta 1 adrenergic receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors

Active Indications (Highest Phase)
Marketed: Essential hypertension


No Inactive Indications

Originator: Merck KGaA

S-Metoprolol/clopidogrel 21 May 2015
Beta 1 adrenergic receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists

Viewing a Drug Profile Record

- From the search results page, you can click the Drug Name to view the full record



Adis Insight

Search: by Mechanism ▼ Beta-blockers

Home • Contact Us

Refine Your Search

Indication

- Cardiovascular disorders 83
- Hypertension 40
- Arrhythmias 26
- Glaucoma 26
- Ocular hypertension 26

Phase

- Marketed 26
- Registered 3
- Pre-registration 2
- Phase III 8
- Phase II/III 2

Location

- Asia 50
- USA 47
- Europe 45
- European Union 43
- Japan 24

Mechanism Of Action

- Beta-adrenergic receptor antagonists 115
- Beta 1 adrenergic receptor antagonists 33
- Calcium channel antagonists 17
- Alpha adrenergic receptor antagonists 15
- Alpha 1 adrenergic receptor antagonists 10

Search results for Mechanism of Action: "Beta-blockers"

115 Drugs 356 Trials 2,027 Safety Reports

Showing 50 of 115 drugs

S-Metoprolol/clopidogrel
Beta 1 adrenergic receptor antagonists; Platelet aggregation inhibitors

Inactive Indications
No development pursued: Cardiovascular disorders; Hypertension
Originator: Emcure Pharmaceuticals

Nebivolol
Beta 1 adrenergic receptor antagonists


Active Indications (Highest Phase)
Marketed: Chronic heart failure; Heart failure; Hypertension

Inactive Indications
Discontinued: Angina pectoris
Originator: Janssen L.P. | Licensed by: Berlin Chemie, CSL, Durex

Carvedilol controlled release - GlaxoSmithKline
Alpha 1 adrenergic receptor antagonists; Beta-adrenergic receptor antagonists

Active Indications (Highest Phase)
Marketed: Heart failure; Hypertension; Left ventricular failure

No Inactive Indications
Originator: Roche | Licensed by: GlaxoSmithKline



◀ Back to search results

◀ Previous Record Next Record ▶

Drug Profile

Nebivolol

Alternative Names: Bystolic; Lobivon; Nebilet; Nebilox; Nebivolol hydrochloride; R 66155; R 65824; R 67555; Solistar

Latest Information Update: 27 Apr 2015

Print Profile

At a glance

Originator	Janssen L.P.
Developer	Duncan, Forest Laboratories; Janssen, Menarini
Class	Antihypertensives; Benzopyrans; Ethanolamines; Fluorobenzenes; Heart failure therapies; Small molecules
Mechanism of Action	Beta 1 adrenergic receptor antagonists
Orphan Drug Status	No
On Fast track	No
New Molecular Entity	Yes

Highest Development Phases

Marketed	Chronic heart failure; Heart failure; Hypertension
Discontinued	Angina pectoris

Most Recent Events

17 Apr 2015 The US FDA approves an ANDA for nebivolol submitted by

Table of Contents

- At a glance
- Development Overview
 - Introduction
 - Company agreements
 - Key development milestones
 - Patent information
- Drug Properties & Chemical Synopsis
- Trial Landscape
- Development Status
 - Summary Table
- Commercial Information
 - Involved Organisations
 - Brand Names
- Related Safety Reports
- Scientific Summary
 - Pharmacokinetic measures
 - Pharmacokinetics

DRUG Profile record includes:


- Table of Contents for easy navigation
- Drug name and synonyms
- Chemical Structure
- At a glance section
- Development Overview
- Drug Properties & Chemical Synopsis
- Trial Landscape
- Development Status
- Commercial Information
- Related Safety Reports
- Scientific Summary section
- Development history table
- Reference section

Drug Profile

Atorvastatin

Alternative Names: Atorvastatin calcium, Cardyl, CI 981, Lipitor, Prevencor, Sortis, Tahor, Xarator 10, YM 548, Zarator

Latest Information Update: 23 Apr 2015



At a glance


Originator	Pfizer
Developer	Astellas Pharma; Laboratorios Phoenix; Pfizer
Class	Amides; Antihyperlipidaemics; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
Mechanism of Action	HMG-CoA reductase inhibitors
Orphan Drug Status	No
On Fast track	No


Table of Contents

- [At a glance](#)
- [Development Overview](#)
 - Introduction
 - Company agreements
 - Key development milestones
 - Patent information
- [Drug Properties & Chemical Synopsis](#)
- [Trial Landscape](#)
- [Development Status](#)

Trial Landscape

Indication	Phase 0	Phase I	Phase II	Phase III	Phase IV
Acute coronary syndromes	-	-	1	1	1
Alzheimer's disease	-	-	1	1	2
Aneurysm	-	-	1	-	-
Angina pectoris	-	-	-	-	3
Aortic valve stenosis	-	-	-	1	1
Atherosclerosis	-	-	5	4	7
Atrial fibrillation	-	-	1	2	5

 Feedback

 Back to top

TRIAL Profile record includes:

- Table of Contents for easy navigation
- At a glance section
- Trial Overview
- Trial Details
- Interventions
- Results
- Authors
- Trial Centres
- Trial History Table
- Reference section

[← Back to search results](#)
[← Previous Record](#)
[Next Record →](#)


Trial Profile

A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin.

Completed

Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2015

 [Print Profile](#)

At a glance

Table of Contents

Results

Therapeutic efficacy

After 104 weeks, dulaglutide was more effective than sitagliptin in patients with type 2 diabetes mellitus who were receiving metformin. The reductions from baseline in the proportion of glycosylated haemoglobin were 0.99%, 0.71% and 0.32% in the dulaglutide 1.5 and 0.75 mg/day and sitagliptin groups, respectively.^[1]

Dulaglutide (0.75 mg/dose) and dulaglutide (1.5 mg/dose) resulted in significantly greater reductions from baseline in the proportion of glycosylated haemoglobin over a 104-week period, compared with sitagliptin (-0.71% and -1.08%, respectively, vs -0.32%; $p < 0.001$), in patients with type 2 diabetes mellitus inadequately controlled with metformin alone.^[1]

In the phase II dose-finding part of this study, dulaglutide (0.75 mg/week) and dulaglutide (1.5 mg/week) were determined as being the most appropriate doses for subsequent phase III testing, based on the composite efficacy and safety endpoint of proportion of glycosylated haemoglobin (52-week sitagliptin adjusted), bodyweight (26-week placebo-adjusted), diastolic blood pressure (26-week placebo-adjusted) and pulse rate (26-week placebo-adjusted), in patients with type 2 diabetes mellitus inadequately controlled with metformin alone. Furthermore, there was at least a 2-fold difference in concentration between doses, meeting another selection criteria.^[2]

The addition of dulaglutide to metformin was more effective than the addition of sitagliptin in patients with uncontrolled type 2 diabetes mellitus. The changes in the proportion of glycosylated haemoglobin at 52 weeks (primary endpoint) were -0.39, -0.87 and -1.10 in the sitagliptin and dulaglutide 0.75 and 1.5 mg/day groups, respectively ($p < 0.001$ for both dulaglutide doses vs sitagliptin).^[1]

Dulaglutide at dosages of 0.75 or 1.5 mg/week was significantly noninferior to sitagliptin with respect to the reduction from baseline in the proportion of glycosylated haemoglobin (HbA1c) over 1 year (primary endpoint) in patients with type 2 diabetes mellitus who were also receiving metformin. Dulaglutide was also shown to be statistically superior to sitagliptin for reduction in HbA1c.^[1]

In metformin-treated patients with type 2 diabetes mellitus, both dosages of dulaglutide (0.75 and



Back to top

SAFETY Profile record includes:

- Drug Name
- Number of cases
- Narrative Summary
- Author Comments
- Country and Language
- Descriptors
- Related Drugs
- Reference Section

Drug Safety : Adverse reaction case report

Lidocaine/articaine

Various toxicities: 4 case reports

Release Date: 19 May 2015





 Print Report

Narrative Summary

A woman and two boys developed redness, itching and oedema at injection site following administration of lidocaine and articaine respectively; one of the boys also developed drowsiness. One more woman developed redness spread all over body and tingling around mouth and lips following administration of lidocaine.

The women aged 58 and 20 years received lidocaine and the boys aged 58 and 12 years were administered articaine [dosages, routes and indications not stated; not all durations of treatments to reaction onsets stated]. One of the woman and the boys developed redness, itching and oedema at injection site following administration of the drugs. The 58-year-old woman developed the reaction 15 minutes after administration of the drug. The 20-year-old woman developed redness spread all over body and tingling around mouth and lips following administration of lidocaine. The patients underwent intradermal test that was negative. Subcutaneous provocation test with lidocaine was negative and with articaine was positive only for one woman. The patients developed urticarial rash, localised redness with itching, headache, nausea or localised urticarial plaque following subcutaneous provocation test with articaine [outcomes not stated].

Related Drugs

Drug Name	Highest Phase	Owner
Lidocaine - Atrix Laboratories 	Discontinued (I)	QLT USA
Lidocaine - MGI GP 	Discontinued (I)	MGI GP
Lidocaine - NanoCyte/Fermdale Laboratories 	Phase II	NanoCyte
Lidocaine - Noven Pharmaceuticals 	No development reported (III)	Noven Pharmaceuticals

DEAL Profile record includes:

- Type of Agreement
- Date of Agreement
- Organizations involved
- Drugs/Indications included
- Narrative about the deal


Manufacturing agreement - 07 Apr 2014

Pacira Pharmaceuticals – Patheon

Drugs: Bupivacaine | **Indications:** Postoperative pain


In April 2014, Pacira Pharmaceuticals, Inc entered into a strategic co-production partnership with Patheon to manufacture and package EXPAREL® (bupivacaine liposome injectable suspension) at Patheon's sterile manufacturing facility in Swindon, United Kingdom. Under the terms of agreement, Patheon will be responsible for the construction of the dedicated manufacturing suites, installation and validation of the manufacturing equipment and the commercial manufacture of EXPAREL. Pacira will oversee the design and purchase of the dedicated EXPAREL manufacturing equipment to be installed in the Patheon facility, lead the technical transfer of the manufacturing process and govern, with on-site and other personnel, the oversight and optimization of the proprietary DepoFoam®-based manufacturing process. [See less](#)

Chemical Structure Search



- From the home page, select the 'STRUCTURE SEARCH' link found to the right of the search bar

Chemical Structure Search



The screenshot shows the 'Search by Structure' interface on the website `adisinsight.springer.com/structure-search`. The page has a header with the title 'Search by Structure' and a sub-header 'Start by drawing a structure'. A toolbar contains various drawing tools: 'Reset', undo, redo, eraser, lasso select, pan, zoom in, zoom out, and a series of ring templates (triangle, square, pentagon, hexagon, heptagon, octagon, nonagon, decagon). Below the toolbar is a large canvas where two chemical structures are drawn: a cyclopentane ring and a cyclopentene ring. On the right side, there is a vertical sidebar with an 'Advanced Search' link at the top, an 'Info' icon, and a 'Back to top' button at the bottom.

- Begin drawing the chemical structure you would like to find
- When you submit, you'll see the relevant results returned


Chemical Structure Search

The screenshot displays the AdisInsight search interface. On the left, a sidebar titled "Refine Your Search" contains filters for Indication, Phase, Location, Mechanism Of Action, Drug Class, Patient Segment, Route Of Administration, Formulation, and Organisation. The main content area shows two chemical structures side-by-side, both highlighted with an orange border. The structure on the left is labeled "Quinupristin" and is a complex polycyclic molecule with multiple amide and ester groups. The structure on the right is labeled "Dalfopristin" and features a central bicyclic core with a sulfonamide group and a hydroxyl group. The browser address bar at the top shows "adisinsight.springer.com/search".

- The relevant results for your Structure search will appear on the results page
- Click the drug name to access the profile
- The chemical structure is immediately available in the upper right corner of the profile OR the png and mol files are available to download in the DRUG PROPERTIES & CHEMICAL SYNOPSIS section

Exporting Data

- The next 7 slides illustrate how users can export content from AdisInsight
- To export data, select EXPORT in right hand corner and select which format you would like to use



The screenshot displays the AdisInsight interface with a sidebar on the left containing filters for Prevention, Monotherapy, Route Of Administration, Formulation, and Organisation. The main content area shows a list of drugs, with 'Vernakalant' and 'GS 6615' highlighted. An orange box highlights the 'Export' button in the top right corner, which has opened a dropdown menu with three options: 'Export Results(CSV)', 'Export Results(BizInt)', and 'Export Data' with a document icon. The interface also shows counts for 278 Drugs, 983 Trials, 5,787 Safety Reports, and 165 Deals. A 'Back to top' button is visible in the bottom right corner.

☐ Prevention 10
☐ Monotherapy 8

Route Of Administration [see all](#)

☐ unspecified 116
☐ PO 91
☐ IV 32
☐ Topical 22
☐ Transdermal 8

Formulation [see all](#)

☐ unspecified 197
☐ Tablet 20
☐ Controlled release 16
☐ Injection 13
☐ Patch 12

Organisation [see all](#)

☐ Nonindustrial source 15
☐ GlaxoSmithKline 13
☐ Pfizer 12
☐ Eisai Co Ltd 9
☐ AstraZeneca 6

278 Drugs 983 Trials 5,787 Safety Reports 165 Deals

Showing 50 of 278 drugs Sort by Update date ▼ Export ▲

Vernakalant
Potassium channel antagonists; Sodium channel antagonists

Active Indications (Highest Phase)
Marketed: Atrial fibrillation

No Inactive Indications

Originator: Cardiome Pharma | Licensed by: AOP Orphan Pharmaceuticals AG; Algorithm; Aspen Pharmacare; Biospifar; Eddingpharm; Eurolab Especialidades Medicinales de Eurofar; Lifepharm; Logista Pharma; Nomeco; Oriola; Tamro AB; Tzamal Medical; UDG Healthcare; Vianex

GS 6615 14 Apr 2015
Sodium channel antagonists


Active Indications (Highest Phase)
Phase III: Arrhythmias
Phase II/III: Hypertrophic cardiomyopathy
Phase I: Ischaemic heart disorders

No Inactive Indications

Originator: Gilead Sciences

Back to top


Exporting Data – Exporting Results (CSV)



The screenshot displays the AdisInsight interface for exporting data. On the left, the 'Refine Your Search' sidebar includes filters for Indication (Neurological disorders, Cardiovascular disorders, Pain, Arrhythmias, CNS disorders), Phase (Marketed, Registered, Preregistration, Phase III, Phase II/III), Location (USA, Europe, European Union, Japan, Canada), and Mechanism Of Action (Ion channel modulators). The main content area shows '278 Drugs' and 'Showing 50 of 278 drugs'. The 'Options' dropdown menu is open, showing 'Key drug properties' selected and 'Detailed development status' as an alternative. Two buttons are visible: 'Export selected 50 drugs (CSV)' and 'Export all 278 drugs (CSV)'. The interface also displays a list of selected properties for export, including Basic drug info, Therapeutic area, Indications, Mechanism of action, Organisation, Alternative Names, Brands (country), Highest development phase, Orphan designation, Adverse events, Antimicrobial Activity, Comparative efficacy, Drug interactions, Immunogenicity, Last Significant Update, Pharmacokinetic characteristics, Pharmacodynamic characteristics, and URL.

- Select Exporting Results CSV, and you can immediately export the entire results set for a specific tab OR the first 50 selected drugs
- Click Options to select which Key drug properties you want to export OR choose to export the detailed development status information

Exporting Data – Exporting Data Table



Showing 50 of 278 drugs Sort by: Update date Export

Export Data X Close

Type:
☐ Single Parameter ☒ Multiple Parameter

Parameter 1: Indication ▼ Parameter 2: Phase ▼

CNS disorders	16	5	5	9
Cancer	-	-	-	-
Cancer pain	-	-	-	1


View Results

Export CSV

- Select Export Data, and you can choose to create a data table grouped by a single or multiple parameter
- Once you click 'View Results' you can drill down to view the profiles for a specific parameter OR you can export into a CSV file

Exporting Data – Export BizInt

- The BizInt Charting Tool provides report templates users can select from
- Select Export Results (BizInt) and choose Export all or selected 50 drugs to BizInt



The screenshot shows the AdisInsight search results page for "Bupivacaine implant - Innocoll". The page is titled "adisinight.springer.com/search". On the left, there are filters for "Adjunctive treatment" (14), "In children" (12), "Prevention" (10), and "Monotherapy" (8). Below these are "Route Of Administration" (see all) and "Formulation" (see all). The main content area shows "278 Drugs", "983 Trials", "5,787 Safety Reports", and "165 Deals". It indicates "Showing 50 of 278 drugs" and "Sort by: Update date". There are two buttons: "Export selected 50 drugs to BizInt" and "Export all 278 drugs to BizInt". The drug entry for "Bupivacaine implant - Innocoll" is shown, with a date of "20 Apr 2015" and a "Back to top" link. The "Active Indications (Highest Phase)" section lists "Phase III: Postoperative pain". The "Inactive Indications" section lists "No development reported: Pain".

Filter	Count
Adjunctive treatment	14
In children	12
Prevention	10
Monotherapy	8

Route Of Administration	Count
unspecified	116
PO	91
IV	32
Topical	22
Transdermal	8

Formulation	Count
unspecified	197

278 Drugs 983 Trials 5,787 Safety Reports 165 Deals

Showing 50 of 278 drugs Sort by: Update date Export

BizInt export options Export selected 50 drugs to BizInt Export all 278 drugs to BizInt

☒ **Bupivacaine implant - Innocoll** 20 Apr 2015 Back to top

Sodium channel antagonists

Active Indications (Highest Phase)


Phase III: Postoperative pain

Inactive Indications

No development reported: Pain

How to use BizInt Charting Tool

- Through AdisInsight, you are able to download and utilize the BizInt Web Charts software to analyze your information. BizIntWeb Charts presents data in tables – also called charts –, a format that assists rapid analysis and informed decision-making. You can change the format of a chart, add your own data to it, save and print it. You can also update a chart to incorporate data that has changed since you created the chart.



Download BizInt from Results page

- Select Export Results(BizInt)
- Select BizInt export options
- ‘Download BizInt setup’
- Select AdisWebCharts.exe file
- Follow Install Wizard instructions

How to use BizInt Charting Tool

Showing 50 of 115 drugs Sort by: Update date ▼ Export ▼

BizInt export options ▼ Export selected 50 drugs to BizInt Export all 115 drugs to BizInt

☒ **S-Metoprolol/clopidogrel** 21 May 2015

Beta 1 adrenergic receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists

Inactive Indications

No development reported: Cardiovascular disorders; Hypertension; Thrombosis

Originator: Emcure Pharmaceuticals

Back to top

1. Select Export
2. Select Export all drugs to BizInt
3. Open file in lower right-hand corner
4. Click 'OK' to create a new chart
5. Select a chart template

Select Initial Chart Template

Select a chart template:



- Chemical Chart
- Clinical Applications Chart
- Company & Commercial Chart
- Credit Suisse Market Status
- Credit Suisse Revenue Forecast (US\$m)
- Development Status Chart
- MMM_2014_Report
- Organisations Chart
- Product Chart**
- Product Pharmacology Chart
- Therapeutic Class Chart

OK Cancel Help

Adis R&D Insight: Product Chart								
	Drug	Synonyms	Fixed Combination	Therapeutic Class (WHO)	Therapeutic Class (EphMRA)	Mechanism Of Action	Chemical/Biological Class	Indication
1	S-Metoprolol/clopidogrel	Smetoprolol extended release/clopidogrel immediate release Emcure	Yes			Beta 1 adrenergic receptor antagonists Platelet aggregation inhibitors Purinergic P2 receptor antagonists	Propanolamines Pyridines Small molecules Thiophenes	Hypertension Cardiovascular disorders (Prevention) Thrombosis (Prevention)
2	Nebivolol	Bystolic Lobivon Nebilet NebiloX Nebivolol hydrochloride R 067555 R 65824 R 67555 Solistar		C07A-B12 (Nebivolol)	C7A (Beta-Blocking Agents, Plain)	Beta 1 adrenergic receptor antagonists	Benzopyrans Ethanolamines Fluorobenzenes Small molecules	Hypertension Heart failure Chronic heart failure Hypertension Heart failure Angina pectoris
3	Carvedilol controlled release - GlaxoSmithKline	Carvedilol phosphate Coreg CR Coreg CR Micropump SKF 105517D		C07A-G02 (Carvedilol)	C7A (Beta-Blocking Agents, Plain)	Alpha 1 adrenergic receptor antagonists Beta-adrenergic receptor antagonists Calcium channel antagonists	Carbazoles Ethanolamines Phenyl ethers Propanolamines Small molecules	Left ventricular dysfunction Hypertension Heart failure

BizInt Charting Tool – Export files

- Once you have created a BizInt Chart, you can export the content to any of the file formats shown below
- By selecting, Excel – optimized HTML, you are able to share content with colleagues who may not be familiar with, or have access to, AdisInsight
- Follow the instructions and name your file, and open the excel spreadsheet
- The excel report allows you to share content with colleagues – the Drug name links directly to the most current profile record for that Drug directly on the AdisInsight platform

	A	B	C
1	Adis R&D Insight: P		
2			
3		Drug	Synonyms
1		Tafluprost/timolol	DE111 TAPCOM Taptiqom Timolol maleate/tafluprost Timolol/tafluprost
4			
5	2	Nebivolol/valsartan	Valsartan/nebivolol
6	3	Amlodipine/bisoprolol	Bisoprolol/amlodipine ConcorAM
		Dorzolamide/timolol	Cosopt Cosopt Mini Cosopt PF L671152/timolol MK507/timolol

Adis Insight by Drug Name

Back to search results Previous Record Next Record

Drug Profile

Tafluprost/timolol

Alternative Names: DE-111; Tafluprost/timolol maleate; TAPCOM; Taptiqom; Timolol maleate/tafluprost; Timolol/tafluprost

Latest Information Update: 15 Jul 2015

At a glance

Originator	Santen Oy; Santen Pharmaceutical
Developer	Asahi Glass; Santen Oy; Santen Pharmaceutical
Class	Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiazoles


Table of Contents


At a glance

Development Overview

- Introduction
- Company agreements
- Key development milestones

Saving Searches



- Once you have logged in with your User Name and Password (slide 5), you will see the 'Save & Alert' button on the search results page
- To save a search, select  and follow instructions
- Access Saved Searches from 'My Workspace'



The screenshot displays the AdisInsight search results interface. On the left, there is a sidebar with the heading 'Indication' and a 'see all' link. Below this, a list of medical conditions is shown with checkboxes and counts: Cardiovascular disorders (83), Hypertension (49), Arrhythmias (28), Glaucoma (28), and Ocular hypertension (28). The main content area features a top right corner with a blue 'Save & Alert' button, which is highlighted with an orange border. Below this, there are four tabs: '115 Drugs' (active), '356 Trials', '2,027 Safety Reports', and '33 Deals'. At the bottom of the main area, it says 'Showing 50 of 115 drugs', 'Sort by: Update date' with a dropdown arrow, and 'Export' with a dropdown arrow.

Saving Searches and Setting up Email Alerts


- You can set up an email alert to inform you when information has changed for a specific search
- On the home page, once you are logged in with your user name and password, you will see 'My Workspace'
- Once you select 'My Workspace' you can access Saved Searches and Alerts




- You can 'Run' saved searches or Create Alerts

Setting up Email Alerts

To Create an alert from 'My Workspace:'

1. Select 'Alerts'
2. Create New
3. Enter a Name for Alert
4. Select the Saved Search you would like to be alerted for
5. Add any additional colleague email
6. Designate Frequency
7. Deselect 'Advise if no updates' if you want to receive an email regardless of whether there are updates included
8. Select  to Save



Create Alert

Alert Name

Name:

Saved Searches

Select from the list of saved searches to receive alerts.

<input type="checkbox"/> MySearch_19052015_152306	Show Query
<input type="checkbox"/> MySearch_17052015_163225	Show Query

Settings

Email Address:

angela.panetta@springer.com x

*Type an email and press enter to add

Alert Frequency:

☐ Daily ☒ Weekly ☐ Monthly

Content:

☒ Drugs ☒ Trials ☒ Safety Reports

☐ Advise if no updates

Filters:

☒ Notify for all event ☐ Choose events to filter

Cancel Create Alert

Setting up Email Alerts

- When setting up an Alert, you can apply additional filters to limit the content you receive via your email alert
- If you choose to filter events, you are then able to deselect the DRUG FILTERS and Phase change to ensure you only receive notification for those limited events

Filters:
☐ Notify for all event ☒ Choose events to filter

Drug Filters:



<input type="checkbox"/> New Profile	<input type="checkbox"/> Active Status Review
<input type="checkbox"/> Regulatory Status	<input type="checkbox"/> Licensing Status
<input type="checkbox"/> Trial Update	<input type="checkbox"/> Company Name Changes
<input type="checkbox"/> Scientific Update	

Phase change to: | [Select all](#)

<input type="checkbox"/> Marketed	<input type="checkbox"/> Registered
<input type="checkbox"/> Preregistration	<input type="checkbox"/> Phase III (Include II/III)
<input type="checkbox"/> Phase II (Include I/II)	<input type="checkbox"/> Phase I
<input type="checkbox"/> Phase 0	<input type="checkbox"/> Market Withdrawal
<input type="checkbox"/> Preregistration Submission Withdrawal	<input type="checkbox"/> Suspended (at any phase)
<input type="checkbox"/> Discontinued (at any phase)	<input type="checkbox"/> No Development Reported (at any phase)

Feedback

- If you would like to ask a question or provide feedback, click the Feedback button located on the left-hand side of each page



- The Feedback button will open a separate window where you can CONTACT SUPPORT or GIVE FEEDBACK

Questions?

- Product: <http://AdisInsight.Springer.com>
- Web: www.springer.com/us/adis
- Email: Ask-the-Expert-AdisInsight@springer.com